This inventor holds 1 USPTO granted patent, plus 2 CIPO patents and 8 EPO patents. Top assignees: Amgen Inc., Ucb S.a.. Active years: 2009.
Company Filing History:
1 out of 2,069 
1 out of 119 
Years Active: 2009
Title: Kelly Sue Hoffmann: Innovator in Sclerostin Research
Introduction
Kelly Sue Hoffmann is a notable inventor based in Newbury Park, California. She has made significant contributions to the field of biotechnology, particularly in the development of sclerostin-binding antibodies. Her work has implications for various therapeutic applications, showcasing her innovative spirit and dedication to advancing medical science.
Latest Patents
Hoffmann holds a patent for a sclerostin-binding antibody. This patent, titled "Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents," provides valuable insights into antibodies capable of binding to the sclerostin protein. This innovation is crucial for understanding and potentially treating conditions related to bone density and metabolism.
Career Highlights
Throughout her career, Hoffmann has worked with prominent companies in the biotechnology sector, including UCB S.A. and Amgen Inc. Her experience in these organizations has allowed her to collaborate with leading experts and contribute to groundbreaking research in her field.
Collaborations
Hoffmann has collaborated with esteemed colleagues such as Christopher J. Paszty and Martyn Kim Robinson. These partnerships have enriched her research and expanded the impact of her innovations in the scientific community.
Conclusion
Kelly Sue Hoffmann is a pioneering inventor whose work on sclerostin-binding antibodies exemplifies the intersection of innovation and biotechnology. Her contributions continue to influence the field and inspire future research endeavors.